Can Kidney Stones Cause Cancer? Potential Risks and Research

Kidney stones are associated with a moderately higher risk of several urinary tract cancers, but whether the stones themselves cause cancer remains an open question. Large population studies consistently show that people with a history of kidney stones develop cancers of the kidney, renal pelvis, ureter, and bladder at higher rates than people without stones. A 2014 meta-analysis pooling seven studies estimated that stone formers faced roughly 76% greater odds of kidney cancer compared to non-stone-formers. Yet the story is more complicated than a single statistic suggests, because the same habits and metabolic conditions that produce stones also raise cancer risk independently, and the extra medical imaging that stone patients undergo catches tumors that might otherwise go unnoticed.

The Statistical Link to Kidney Cancer

The most robust evidence comes from pooled analyses. A systematic review and meta-analysis found that a history of kidney stones was tied to a pooled relative risk of 1.76 for renal cell carcinoma, the most common type of kidney cancer.¹ That same analysis found a striking sex difference: the elevated risk was statistically significant in men but not in women. A large Dutch cohort study refined this further. It found that the overall risk of renal cell carcinoma was about 39% higher in people who had had stones, but when researchers broke the cancers down by subtype, the elevated risk was concentrated in papillary renal cell carcinoma, which carried roughly triple the risk, while the more common clear-cell subtype showed no significant increase at all.²

A more recent analysis using U.S. national survey data reported even stronger associations, with kidney stone history linked to roughly doubled odds of renal cell carcinoma. But the same study applied a technique called Mendelian randomization, which uses genetic variants as stand-ins for the exposure to test whether the link is likely causal at a biological level, and found no evidence of a direct genetic causal pathway between stones and any of the cancers examined.³ That disconnect is important. It suggests that shared risk factors or the biological consequences of having stones, rather than whatever genetic tendency makes a person form stones in the first place, may be driving the association.

Upper Tract Urothelial Carcinoma

If there is one cancer subtype where the kidney-stone connection looks strongest, it is upper tract urothelial carcinoma, or UTUC. These are cancers that arise in the lining of the renal pelvis or the ureter, exactly where stones sit and cause the most mechanical and chemical irritation. A 2025 meta-analysis calculated that stone formers had about two-and-a-half times the risk of developing UTUC compared to people without stones.⁴ The Netherlands Cohort Study, looking at this same cancer, found a 66% increase in risk among stone formers.²

Beyond just developing UTUC, there is emerging evidence that stone history affects outcomes after diagnosis. A 2025 study found that among patients already diagnosed with upper tract urothelial carcinoma, those who had a prior stone history had significantly worse cancer-specific survival and disease-free survival compared to patients without stones.⁵ Whether this reflects a more aggressive tumor biology driven by chronic irritation or some confounding factor remains unclear, but the finding underscores why urologists pay close attention to stone patients who develop blood in the urine.

Bladder Cancer and Stones Lower in the Tract

The association extends beyond the kidney itself. A large Swedish registry study following patients hospitalized for kidney or ureteral stones found a 40% increase in bladder cancer incidence, with women showing a risk more than twice as high as men.⁶ The same study found a two-and-a-half-fold excess of renal pelvis and ureteral cancers. The NHANES-based analysis cited earlier also found a strong association between stones and bladder cancer, with odds roughly 2.7 times higher in stone formers, though again, Mendelian randomization did not support a direct genetic causal link.³

Why women might face a proportionally higher bladder cancer risk from stones is not well understood. One theory is that because bladder cancer is rarer in women overall, the relative increase from stone-related inflammation stands out more sharply. Another possibility is that recurrent urinary tract infections, which are more common in women with stones, contribute additional inflammatory insult to the bladder lining.

How Stones Could Promote Cancer

Several biological pathways have been proposed to explain the association, and they are not mutually exclusive.

Chronic inflammation sits at the center of most theories. When a stone lodges in the kidney or ureter, the surrounding tissue mounts an ongoing immune response. This sustained inflammation drives oxidative stress, which damages DNA and can push cells toward uncontrolled growth. The relationship runs in both directions: oxidative stress also promotes further stone formation, creating a self-reinforcing loop.⁷ Think of it as a low-grade fire that never fully goes out, giving the tissue repeated opportunities to accumulate harmful mutations.

When inflammation persists long enough, the normal lining cells of the renal pelvis can undergo a transformation called squamous metaplasia. The urothelial cells gradually take on a different character, and in some cases this changed tissue eventually becomes cancerous. This pathway is best documented with large staghorn stones that sit in the renal pelvis for years or decades.⁸ Squamous cell carcinoma of the renal pelvis is rare, but when it does occur, it is almost always found alongside longstanding stone disease.⁹ This is one scenario where the causal argument is at its most convincing: the stone causes ongoing tissue damage, the tissue changes its cellular identity in response, and that changed tissue eventually turns malignant.

Researchers have also begun exploring the role of the microbiome. Both the gut and the urinary tract harbor communities of bacteria that influence stone formation and potentially cancer risk. Dysbiosis, an imbalance in these microbial communities, has been linked to kidney stone disease, and some researchers propose that these same microbial shifts may contribute to the development of papillary renal cell carcinoma.¹⁰ This line of research is still in its early stages, but it offers an intriguing mechanism that goes beyond simple mechanical irritation.

Why Causation Is So Hard to Prove

The central difficulty is disentangling stones from everything that comes with them. People who form kidney stones are more likely to smoke, drink alcohol, carry excess weight, and eat diets that independently raise cancer risk.¹¹ Studies try to adjust for these factors, but no observational design can perfectly separate the effect of the stone itself from the metabolic environment that produced it.

Detection bias is another significant confounder. Stone patients get a lot of imaging. CT scans ordered for kidney stone episodes routinely uncover masses that were never causing symptoms and might not have been found for years, if ever, in someone who never had a scan. One study of unenhanced CT scans found that about 14% of patients had at least one incidental renal mass, the vast majority of which turned out to be benign.¹² Still, the small fraction that are indeterminate or malignant means that stone patients are selectively funneled into cancer diagnoses simply because they are being looked at more closely. This surveillance effect inflates the apparent risk, and it is nearly impossible to quantify how much of the observed association it explains.

The Mendelian randomization evidence adds another layer. If kidney stones directly caused cancer, you would expect the genetic variants that predispose people to stones to also predict cancer risk. They do not, at least not in the analyses done so far.³ This does not completely rule out causation, because the biological damage from stones (inflammation, infection, tissue remodeling) may not be captured by the specific genetic instruments used. But it does suggest that the relationship is more complex than “stones cause cancer” and may be substantially driven by shared environmental and metabolic exposures.

Genetic Overlap Between Stone Disease and Kidney Cancer

At the far end of the spectrum from garden-variety calcium stones are rare inherited metabolic syndromes where both kidney stones and cancer susceptibility trace to mutations in the same gene. A 2025 review compiled a curated list of 64 single-gene causes of kidney stones and 50 genes that predispose to kidney cancer, with overlap between the two lists in several conditions.¹³ Hereditary leiomyomatosis and renal cell carcinoma, for instance, is caused by mutations in the fumarate hydratase gene and produces both recurrent calcium oxalate stones and aggressive papillary kidney cancers, sometimes in young adults. Birt-Hogg-Dubé syndrome, tuberous sclerosis complex, and von Hippel-Lindau disease are other examples where kidney tumors and stones can co-occur because of the same underlying genetic defect.

These conditions are rare, but they matter clinically because missing the diagnosis can be life-threatening. If you have recurrent stones that started at an unusually young age, a strong family history of both stones and kidney tumors, or stones with unusual chemical composition, genetic testing may uncover a syndrome that warrants cancer screening protocols you would not otherwise receive.

Shock Wave Lithotripsy and Long-Term Kidney Health

Shock wave lithotripsy, or SWL, has been a go-to treatment for kidney stones since the 1980s. It works by directing focused energy waves through the body to shatter stones into fragments small enough to pass naturally. While effective, the procedure is not completely benign. SWL can cause vascular damage to the kidney and surrounding tissue, potentially leading to scarring and permanent loss of functioning kidney tissue.¹⁴ Some retrospective studies have raised the possibility that repeated SWL treatments could be linked to chronic effects including hypertension and even diabetes, though these findings remain debated and have not been confirmed in prospective trials.

Whether SWL itself raises cancer risk is even less clear. A handful of studies have explored this question, but the data are thin and contradictory. The tissue damage from shock waves is real, but whether it rises to the level of a meaningful cancer promoter in humans is unknown. For most patients with uncomplicated stones, the proven benefit of stone removal still clearly outweighs these theoretical risks. The concern is more relevant for patients who undergo many treatments over a lifetime, where cumulative kidney trauma could add up.

When Blood in the Urine Deserves Extra Attention

One of the most practical implications of the stone-cancer association is how clinicians handle hematuria, or blood in the urine. In a person with known kidney stones, blood in the urine is almost always attributed to the stone. And most of the time, that explanation is correct. But because stone patients have a higher background rate of urinary tract cancers, there is a real risk of writing off hematuria as “just the stone” when it is actually the first sign of a tumor.

This is especially important when the hematuria persists after a stone has passed or been treated, when it appears without the typical colicky pain of a stone episode, or when it occurs in someone with additional risk factors like a long smoking history. In those situations, further workup with cystoscopy or cross-sectional imaging with contrast is warranted even if a stone has been documented. The presence of a stone does not rule out a coexisting malignancy, and the two conditions can be present simultaneously.

Reducing Stone Recurrence and Its Downstream Risks

If chronic stone disease is part of what drives cancer risk, then preventing stones from forming in the first place is a logical way to lower that risk. Standard preventive measures, when followed consistently, can cut stone recurrence by roughly half to 60%.¹⁵ The cornerstone of prevention is straightforward: drink enough fluid to produce at least two to two-and-a-half liters of urine per day, limit sodium intake, get adequate dietary calcium from food rather than supplements, and moderate animal protein consumption.¹⁶ Medications like thiazide diuretics and potassium citrate provide additional benefit for people whose metabolic profile warrants them. The best prevention plan is individualized based on stone composition and a 24-hour urine analysis.¹⁷

Quitting smoking deserves special mention here. Smoking is a risk factor for both kidney stones and virtually every urinary tract cancer. If you have stones and you smoke, addressing the smoking arguably does more for your cancer risk than any stone-specific intervention.

The Psychological Burden of Stones and Cancer Worry

People who deal with recurrent kidney stones carry a real psychological burden. A systematic review and meta-analysis found a moderate association between stone disease and anxiety, and higher rates of depression and psychological distress compared to people without stones.¹⁸ Adding cancer anxiety on top of an already stressful condition is a legitimate concern, and it is worth putting the risk numbers in perspective.

Even with a doubled relative risk, kidney cancer remains uncommon in the general population. In most Western countries, the lifetime risk of kidney cancer is somewhere around 2%. Doubling a 2% risk gives you a 4% risk, which means that 96 out of 100 stone formers will never develop kidney cancer. The relative increases look alarming as ratios, but the absolute risk for any individual stone patient remains low. The numbers are worth knowing not so they can keep you up at night but so you can have an informed conversation with your urologist about appropriate surveillance, especially if you have additional risk factors like a long history of stones, a smoking history, or a family pattern of kidney tumors.